CClinicalTrials.gg
CompletedNCT03622073Updated Mar 11, 2022

Misoprostol Treatment of Mid Trimester Incomplete Abortion by Midwives and Doctors in Uganda.

An interventional study of Misoprostol treatment by Midwife and Misoprostol treatment by Doctor in Incomplete Abortion, sponsored by Makerere University. Completed at 14 sites in Uganda. Open to female participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by Makerere University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,191
Allocation
Randomized
Ages
15 Years and older
Sex
Female
01

Study summary

It is estimated that 47,000 women die every year due to consequences of unsafe abortion globally. The majority of pregnancy related deaths occur in low income countries where induced abortion is restricted, unmet need for contraception is high, and women's status is low. Uganda has a high total fertility rate of 5.4 children per woman, low contraceptive prevalence rate of 39%, and more than half of these pregnancies are unintended. Induced abortion is controversial and restricted in Uganda and legally permitted only to save a woman's life. As a result, women often resort to unsafe abortion- that's either performed by a person lacking the necessary skills or in an environment that does not conform to minimal medical standards. Of the estimated 314,304 women who undergo unsafe abortions each year in Uganda, about 41% receive treatment for complications. This equates to an annual rate of 12 per 1,000 women aged 15-49 years being hospitalized for induced abortion complications, which is considered high in international comparison. In Uganda, outside the larger hospitals and private settings, access to safe post abortion care and surgical facilities are scarce. Studies have showed that trained midwives can deliver safe, effective and acceptable post abortion care using misoprostol in the first trimester. Currently in Uganda, treatment of second trimester incomplete abortion is restricted to physicians. This study will provide evidence on whether treatment for incomplete abortion using misoprostol by mid-level providers can be extended to the early second trimester period. The investigators hypothesize that misoprostol treatment for incomplete second trimester abortion provided by midwives is equivalent to that of physicians requiring no further surgical intervention. Women with incomplete abortion will be randomly allocated to undergo a clinical assessment and treatment with misoprostol either by physician or midwife with safety and effectiveness as main outcomes in the RCT carried out in hospital and high volume health centres in Central Uganda.

Read the detailed description

This randomized controlled equivalence trial (RCT) implemented at eight hospitals and Health centres in Central Uganda will include 1192 eligible women with incomplete abortion of uterine size >12 weeks up to 18 weeks. Following informed consent, each participant will be randomly assigned to undergo a clinical assessment and treatment by either a midwife (intervention arm) or physician (control arm); receive 400mcg of misoprostol administered sublingually 3 hourly up to 5 doses within 24 hours at the health facility until a complete abortion is confirmed. Women who do not achieve a complete abortion within 24 hours will undergo a surgical method of uterine evacuation. Pre-discharge information on danger signs, contraceptive counselling and provision will be done with follow up 14 days later to assess secondary outcomes and acceptability. Analyses will be by Intention-to-Treat (ITT). Background characteristics and outcomes will be presented using descriptive statistics. Differences between groups will be analyzed using risk difference (95% CI) and equivalence established if it lies between the pre-defined range of -5% to +5%. Chi-square test will be used for comparison of outcome and t test used to compare mean values. P-values equal to or lower than 0.05 will be considered statistically significant.

02

Conditions studied

  • Incomplete Abortion

Browse trials for

Keywords

  • Post abortion care
  • Misoprostol
  • Second trimester
03

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Vaginal bleeding
  • With or without contractions with a uterine size > 12 weeks to \< 18 weeks
  • History of partial expulsion
  • Open cervical os.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to misoprostol,
  • Unstable hemodynamic status (systolic blood pressure \< 90mmHg) and shock
  • Signs of pelvic infection and/or sepsis
  • Previous caesarean delivery/uterine scar
  • Suspected extra uterine pregnancy.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
1,191 participants (actual)

Study arms

  • Experimental
    Misoprostol treatment by Midwife

    Administration of misoprostol by the midwife and assessment for the primary outcome.

    Other: Misoprostol treatment by Midwife

  • Active comparator
    Misoprostol treatment by Doctor

    Administration of misoprostol by the doctor and assessment for the primary outcome.

    Other: Misoprostol treatment by Doctor

Interventions

  • OtherMisoprostol treatment by Midwife

    Medical management of incomplete abortion

  • OtherMisoprostol treatment by Doctor

    Medical management of incomplete abortion

05

What researchers measure

Primary outcomes

  1. Complete abortion

    Number of participants who will have expelled all the products of conception as evidenced by cessation of abdominal cramps, vaginal bleeding and closed cervical os.

    Time frame: 24 hours from treatment initiation

Secondary outcomes

  1. Excessive vaginal bleeding

    Participant reporting use of more than 3 pads in an hour.

    Time frame: 24 hours from treatment initiation

  2. Abdominal Pain

    Pain will be defined as discomfort experienced in the lower abdomen using a visual analogue scale with a minimum score of zero representing no pain and a maximum score of 10 representing most pain. A higher score represents a worse outcome.

    Time frame: 24 hours from treatment initiation

  3. Unscheduled visits

    Participant presenting at the study site when not expected

    Time frame: 14-28 days post treatment

  4. Women's acceptability of the post abortion care provider

    Acceptability will be positive reporting of treatment experience, recommendation of method to a friend or reuse of same method.

    Time frame: 14-28 days post treatment

06

Study locations

14 sites
  • Entebbe Hospital
    Entebbe, Uganda
  • Gombe Hospital
    Gombe, Uganda
  • Kawempe Hospital
    Kampala, Uganda
  • Kayunga Hospital
    Kayunga, 256, Uganda
  • Kawolo Hospital
    Lugazi, 256, Uganda
  • Luwero HC IV
    Luwero, Uganda
  • Masaka Hospital
    Masaka, Uganda
  • Mityana Hospital
    Mityana, Uganda
  • Mpigi HC IV
    Mpigi, Uganda
  • Kiganda HC IV
    Mubende, 256, Uganda
  • Mukono HC IV
    Mukono, Uganda
  • Nakaseke Hospital
    Nakaseke, Uganda
  • Kasangati HC IV
    Wakiso, 256, Uganda
  • Wakiso HC IV
    Wakiso, 256, Uganda
07

References and documents

Publications

  • Faundes A. Strategies for the prevention of unsafe abortion. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 1:S68-71. doi: 10.1016/j.ijgo.2012.03.021. Epub 2012 Aug 9. PubMed 22883917 ↗
  • Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, Rossier C, Gerdts C, Tuncalp O, Johnson BR Jr, Johnston HB, Alkema L. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet. 2016 Jul 16;388(10041):258-67. doi: 10.1016/S0140-6736(16)30380-4. Epub 2016 May 11. PubMed 27179755 ↗
  • Uganda Bureau of Statistcs (UBOS) and ICF. 2017. Uganda Demographic and Health Survey 2016: Key Indicators Report. Kampala, Uganda: UBOS, and Rockville, Maryland, USA: UBOS and ICF.
  • Hussain R. Unintended pregnancy and abortion in Uganda. Issues Brief (Alan Guttmacher Inst). 2013 Jan;(2):1-8. PubMed 23550324 ↗
  • Prada E, Atuyambe LM, Blades NM, Bukenya JN, Orach CG, Bankole A. Incidence of Induced Abortion in Uganda, 2013: New Estimates Since 2003. PLoS One. 2016 Nov 1;11(11):e0165812. doi: 10.1371/journal.pone.0165812. eCollection 2016. PubMed 27802338 ↗
  • Mark AG, Edelman A, Borgatta L. Second-trimester postabortion care for ruptured membranes, fetal demise, and incomplete abortion. Int J Gynaecol Obstet. 2015 May;129(2):98-103. doi: 10.1016/j.ijgo.2014.11.011. Epub 2015 Jan 19. PubMed 25660084 ↗
  • Klingberg-Allvin M, Cleeve A, Atuhairwe S, Tumwesigye NM, Faxelid E, Byamugisha J, Gemzell-Danielsson K. Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. Lancet. 2015 Jun 13;385(9985):2392-8. doi: 10.1016/S0140-6736(14)61935-8. Epub 2015 Mar 27. PubMed 25817472 ↗
  • Cleeve A, Byamugisha J, Gemzell-Danielsson K, Mbona Tumwesigye N, Atuhairwe S, Faxelid E, Klingberg-Allvin M. Women's Acceptability of Misoprostol Treatment for Incomplete Abortion by Midwives and Physicians - Secondary Outcome Analysis from a Randomized Controlled Equivalence Trial at District Level in Uganda. PLoS One. 2016 Feb 12;11(2):e0149172. doi: 10.1371/journal.pone.0149172. eCollection 2016. PubMed 26872219 ↗
  • Moran M, Ortega J, Hodoglugil NN. Osur et al.'s Implementation of misoprostol for postabortion care in Kenya and Uganda: a qualitative evaluation. Glob Health Action. 2012 Jul 18;6:21786. doi: 10.3402/gha.v6i0.21786. No abstract available. PubMed 23870184 ↗
  • Pongsatha S, Tongsong T. Randomized controlled trial comparing efficacy between a vaginal misoprostol loading and non-loading dose regimen for second-trimester pregnancy termination. J Obstet Gynaecol Res. 2014 Jan;40(1):155-60. doi: 10.1111/jog.12147. Epub 2013 Sep 5. PubMed 24033985 ↗
  • Dawson AJ, Buchan J, Duffield C, Homer CS, Wijewardena K. Task shifting and sharing in maternal and reproductive health in low-income countries: a narrative synthesis of current evidence. Health Policy Plan. 2014 May;29(3):396-408. doi: 10.1093/heapol/czt026. Epub 2013 May 8. PubMed 23656700 ↗
  • Nabudere H, Asiimwe D, Mijumbi R. Task shifting in maternal and child health care: an evidence brief for Uganda. Int J Technol Assess Health Care. 2011 Apr;27(2):173-9. doi: 10.1017/S0266462311000055. Epub 2011 Mar 30. PubMed 21450128 ↗
  • Atuhairwe S, Hanson C, Atuyambe L, Byamugisha J, Tumwesigye NM, Ssenyonga R, Gemzell-Danielsson K. Evaluating women's acceptability of treatment of incomplete second trimester abortion using misoprostol provided by midwives compared with physicians: a mixed methods study. BMC Womens Health. 2022 Nov 5;22(1):434. doi: 10.1186/s12905-022-02027-y. PubMed 36335344 ↗
  • Atuhairwe S, Byamugisha J, Kakaire O, Hanson C, Cleeve A, Klingberg-Allvin M, Tumwesigye NM, Gemzell-Danielsson K. Comparison of the effectiveness and safety of treatment of incomplete second trimester abortion with misoprostol provided by midwives and physicians: a randomised, controlled, equivalence trial in Uganda. Lancet Glob Health. 2022 Oct;10(10):e1505-e1513. doi: 10.1016/S2214-109X(22)00312-6. Epub 2022 Aug 26. PubMed 36030801 ↗
  • Atuhairwe S, Byamugisha J, Klingberg-Allvin M, Cleeve A, Hanson C, Tumwesigye NM, Kakaire O, Danielsson KG. Evaluating the safety, effectiveness and acceptability of treatment of incomplete second-trimester abortion using misoprostol provided by midwives compared with physicians: study protocol for a randomized controlled equivalence trial. Trials. 2019 Jun 21;20(1):376. doi: 10.1186/s13063-019-3490-5. PubMed 31227019 ↗

Individual participant data

Plan to share: Yes — Deidentified data will be available on request for systematic reviews. The particular data shared will depend on the request.

08

Registry details

Key details

Study ID
NCT03622073
Lead sponsor
Makerere University
Collaborators
Karolinska Institutet, London School of Hygiene and Tropical Medicine
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Aug 14, 2018
Primary completion
Nov 16, 2021
Completion
Dec 16, 2021
Last update
Mar 11, 2022

Study contacts

Kristina G Danielsson, PhD
principal investigator · Karolinska Institutet
Josaphat Byamugisha, PhD
principal investigator · Makerere University
Susan Atuhairwe, MD
principal investigator · Makerere University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion